The efficacy of macrolides in the treatment of bronchiectasis colonised by Ps aeruginosa Source: Eur Respir J 2004; 24: Suppl. 48, 638s Year: 2004
Exploring the susceptibility of P. aeruginosa biofilms in human mucus towards tobramycin treatment Source: International Congress 2017 – Cystic fibrosis: clinical issues Year: 2017
Novel Pseudomonas aeruginosa scoring system to guide empiric anti-pseudomonal therapy in COPD patients with community-acquired pneumònia Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections Year: 2020
Inhibitory activity of azithromycin on pseudomonas aeruginosa in biofilms Source: Eur Respir J 2003; 22: Suppl. 45, 450s Year: 2003
Inhaled phage therapy for the treatment of acute Pseudomonas aeruginosa lung infections Source: International Congress 2018 – Mechanisms of respiratory infection Year: 2018
Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis Source: Eur Respir J , 49 (4) 1600851; DOI: 10.1183/13993003.00851-2016 Year: 2017
In vitro activity of colistin in combination with N-acetylcysteine against Pseudomonas aeruginosa Source: International Congress 2018 – Cystic fibrosis in paediatric patients: current research Year: 2018
Eradication treatment in Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) on patients with pseudomonas aeruginosa Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections Year: 2017
Anti-inflammatory properties of nimesulide and clarithromycin: a comparative study during the therapy of bronchial sepsis involving P.aeruginosa Source: Eur Respir J 2002; 20: Suppl. 38, 373s Year: 2002
The effect of erythromycin on the chronic lower airway infection by pseudomonas aeruginosa Source: Eur Respir J 2004; 24: Suppl. 48, 640s Year: 2004
Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis}, Source: Eur Respir J 2012; 40: 1014-1023 Year: 2012
Comparative in vitro activity of fluoroquinolones against P. aeruginosa isolated from Greek CF patients Source: Virtual Congress 2020 – Microbiology and antimicrobial strategies in cystic fibrosis Year: 2020
Long term treatment with azithromycin in chronic respiratory infections with pseudomonas aeruginosa Source: Eur Respir J 2006; 28: Suppl. 50, 558s Year: 2006
Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2014; 43: 884-897 Year: 2014
The clinical impact of nebulised antibiotics in adults with bronchiectasis and chronic pseudomonas aeruginosa Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020
Effects of direct lung dosing of Tobramycin in a rat chronic infection model using Pseudomonas aeruginosa RP73 Source: International Congress 2018 – Mechanisms of respiratory infection Year: 2018
Highly concentrated aerosolized tobramycin in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection Source: Eur Respir J 2005; 26: Suppl. 49, 620s Year: 2005
Acquired resistance to macrolides in Pseudomonas aeruginosa from cystic fibrosis patients Source: Eur Respir J, 49 (5) 1601847; 10.1183/13993003.01847-2016 Year: 2017
Antibiotic efficacy varies based on the infection model and treatment regimen for Pseudomonas aeruginosa Source: Eur Respir J, 55 (3) 1802456; 10.1183/13993003.02456-2018 Year: 2020